#sat3247
LightNews LightNews
rarediseaseadvisor.bsky.social
@satellosbio.bsky.social announced that the first patient has been dosed in a phase 2 pediatric #ClinicalTrial evaluating SAT-3247, an investigational therapy for #Duchenne muscular dystrophy (#DMD).

Learn more: https://bit.ly/46cLHQH

#RareDisease #SAT3247 #MedSky
First Patient Dosed in Phase 2 Pediatric Trial Evaluating SAT-3247 for DMD
The first participant has received treatment in the BASECAMP trial evaluating SAT-3247, an investigational AAK1 inhibitor for DMD.
bit.ly
February 19, 2026 at 8:11 PM
dmdwarrior.com
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Source: ir.satellos.com/news/news-de...

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #satellos #sat3247 #sat-3247
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247 Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247 Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247 Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
December 11, 2024 at 5:38 PM
theakarifoundation.bsky.social
🔗Lee el artículo completo en el siguiente link: https://theakarifoundation-pr.org/blog

Da clic en el link de nuestro perfil y visita nuestros ARTÍCULOS más recientes.

#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #SatellosBioscience #TRAILHEAD #SAT3247
July 14, 2026 at 6:15 PM